IPQC & FPQC QUALITY CONTROL TESTS FOR SOLID ORAL DOSAGE FORM

Research Scholar: *Kakad Anamika B, Radhika Sanjay Katpale, Vaibhav khemnar, Kandalkar Vaishali P, Manchare Mayuri P.*

Email id: anamikakakad@gmail.com, vaishali2000arm@gmail.com, vaibhavkhemnar2016@gmail.com, radhikakatpale489@gmail.com, mancharemayuri13@gmail.com

Abstract:

Quality control (QC) is a critical component in ensuring the safety, efficacy, and consistency of pharmaceutical products, particularly solid oral dosage forms such as tablets and capsules. In-process quality control (IPQC) and finished product quality control (FPQC) tests are essential in maintaining these standards throughout the manufacturing process. IPQC focuses on monitoring and controlling the production processes to identify and rectify any deviations that may affect the product's quality before completion. Key IPQC tests include visual inspection, hardness, friability, dissolution, and weight variation. These tests ensure that intermediate products meet predefined specifications and are consistent across batches. FPQC, on the other hand, involves evaluating the final product to ensure it meets all required specifications for safety, efficacy, and quality. This stage typically includes tests for content uniformity, dissolution profiles, disintegration time, assay, and impurity testing. The results from both IPQC and FPQC help identify potential issues early in the production process and provide assurances that the final product will perform as intended in the market. These abstract aims to provide an overview of the essential IPQC and FPQC tests performed on solid oral dosage forms, emphasizing their importance in ensuring pharmaceutical quality and regulatory compliance. Through the integration of both stages of quality control, pharmaceutical manufacturers can deliver high-quality products that meet both consumer and regulatory expectations. Quality control (QC) is a fundamental aspect of pharmaceutical manufacturing, ensuring that products meet stringent standards for safety, efficacy, and consistency. In the production of solid oral dosage forms such as tablets, capsules, and granules, two crucial components of the quality control process are In-Process Quality Control (IPQC) and Finished Product Quality Control (FPQC). These tests play an indispensable role in verifying that the pharmaceutical product complies with established specifications, regulatory guidelines, and the required therapeutic outcomes. In-Process Quality Control (IPQC) focuses on monitoring the various stages of the manufacturing process.

Keywords: IPQC, FPQC, quality control, solid oral dosage forms, tablets, capsules, manufacturing process, in-process testing, finished product testing, dissolution, disintegration, assay, content uniformity, friability, etc.

Introduction:

Quality control (QC) is a cornerstone of the pharmaceutical industry, ensuring that products consistently meet the required standards for safety, efficacy, and consistency. In the case of solid oral dosage forms, such as tablets and capsules, QC plays an especially critical role in ensuring that the final product performs as intended. Pharmaceutical manufacturers are responsible for ensuring that the entire production process, from raw material handling to the final product, adheres to strict quality specifications and regulatory guidelines. In-Process Quality Control (IPQC) and Finished Product Quality Control (FPQC) are two pivotal elements within the broader QC framework. IPQC is focused on monitoring and controlling the production processes during various stages of manufacturing, including mixing, granulation, compression, and coating. The goal of IPQC is to detect and correct any deviations early, preventing defects that could compromise product quality before completion. This stage involves a wide range of tests that evaluate the physical and chemical properties of the intermediate products, ensuring consistency and uniformity. FPQC, conducted after the manufacturing process is completed, verifies that the final product meets all necessary specifications and regulatory requirements before it reaches the market.

FPQC testing includes evaluating aspects such as the content uniformity, dissolution rate, disintegration time, assay, and impurity levels. These tests help confirm the safety, efficacy, and compliance of the product with regulatory standards, ensuring that it performs as intended when administered to patients. The integration of both IPQC and FPQC ensures a seamless and thorough quality control system that safeguards product quality throughout the manufacturing process and guarantees that only safe, effective, and high-quality products reach the consumer. This introduction highlights the significance of these two control mechanisms in the production of solid oral dosage forms, underscoring their role in maintaining product integrity, regulatory compliance, and consumer trust.

Fig 1. Dosage form composistion

The pharmaceutical industry is held to rigorous standards to ensure that medications are both safe and effective for patients. One of the most important aspects of this is ensuring the quality of pharmaceutical products, which is why **Quality Control (QC)** is essential throughout the entire manufacturing process. For solid oral dosage forms such as tablets, capsules, and granules, QC guarantees that every batch produced is consistent, reliable, and of high quality. These dosage forms are the most commonly used in modern medicine, making it crucial to maintain strict quality standards to safeguard public health and ensure therapeutic efficacy.

In-Process Quality Control (IPQC) and **Finished Product Quality Control (FPQC)** are integral components of this quality assurance framework. IPQC is focused on monitoring and controlling critical parameters during the production stages. As manufacturing processes are complex and involve numerous variables, there is a constant risk of deviations that could affect the quality of the product. Through IPQC, manufacturers can address issues at early stages, allowing for timely corrections that help minimize risks, reduce wastage, and improve batch-to-batch consistency. Tests conducted during the production phases include monitoring weight variation, hardness, friability, moisture content, dissolution rates, and more. These tests ensure that intermediate products are within specification before moving on to the next stage of production.

Once the manufacturing process is completed, **Finished Product Quality Control (FPQC)** ensures that the final product meets all regulatory and safety standards before it reaches consumers. FPQC tests go beyond monitoring the physical characteristics of the product to include detailed analysis for chemical properties, microbiological safety, and the therapeutic performance of the final product. Key tests in FPQC include dissolution testing, which evaluates how quickly and effectively a drug releases its active ingredient in the body; content uniformity, which checks for consistency in drug concentration across units; and impurity testing, which assesses the presence of harmful substances or contaminants. These tests are conducted in compliance with guidelines from regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the International Council for Harmonisation (ICH), ensuring that products meet not only industry standards but also the high expectations of healthcare professionals and patients.

The ultimate goal of both IPQC and FPQC is to ensure that every tablet, capsule, or solid dosage form produced is effective, safe, and free from defects that could compromise patient health or the integrity of the drug. By combining these two stages of quality control, pharmaceutical manufacturers can address quality concerns proactively, optimize production processes, and meet regulatory requirements, ultimately producing products that meet the highest standards of pharmaceutical excellence. The integration of both IPQC and FPQC not only ensures compliance with regulations but also builds confidence in the quality of pharmaceutical products, fostering trust between manufacturers, healthcare providers, and patients. This paper will delve deeper into the specific tests performed during IPQC and FPQC, exploring the techniques, standards, and guidelines that govern these quality control processes. Additionally, it will emphasize the role of these tests in ensuring the overall quality and safety of solid oral dosage forms, from the initial stages of manufacturing to the final product release.

Universal and IPQC Tests for Solid Oral Dosage Forms

In the pharmaceutical industry, ensuring the quality of solid oral dosage forms like tablets and capsules is of utmost importance. Various tests are performed during the manufacturing process to ensure these products meet the necessary quality standards. These tests can be broadly categorized into **universal tests** and **In-Process Quality Control (IPQC) tests**. Both types of tests help manufacturers monitor the production process, ensuring the consistency, safety, and efficacy of the final product.

Universal Tests

Universal tests are general quality control tests performed on solid oral dosage forms regardless of the specific product. These tests ensure that the basic quality attributes of the dosage form are maintained consistently across different batches and manufacturing runs. The most common universal tests include:

1. **Weight Variation Test**:
    - This test ensures that each dosage unit contains the proper amount of active pharmaceutical ingredient (API) and excipients.
    - The weight of individual tablets or capsules is checked, and deviations from the average weight are considered a failure. This test ensures uniformity in the weight of each unit, preventing dosage errors.
2. **Content Uniformity Test**:
    - This test ensures that the API is uniformly distributed throughout each dosage unit (tablet or capsule).
    - The content of the active ingredient in several units is analyzed and compared to the required specifications. The variability of the content between units must be within a defined range to ensure therapeutic effectiveness.
3. **Dissolution Test**:
    - The dissolution test measures how the active ingredient is released from the dosage form under specific conditions.
    - This test is critical because it determines whether the drug will dissolve in the digestive system at the appropriate rate, which is essential for proper drug absorption and efficacy.
4. **Disintegration Test**:
    - The disintegration test evaluates the time required for the dosage form to break down into smaller particles in a specified liquid medium.
    - The faster the tablet disintegrates, the quicker the drug can be absorbed. This is a crucial test for ensuring that the drug is bioavailable once ingested.



Fig 1.disintigration tester

5. **Hardness/Friability Test**:
    - **Hardness** tests determine the force required to break a tablet, ensuring that it has the proper mechanical strength for handling and transportation.
    - **Friability** tests measure the tendency of tablets to break or crumble during handling. A tablet that is too brittle could disintegrate prematurely, reducing its effectiveness.
6. **Uniformity of Dose**:
    - This test checks the uniformity of the dosage of the active ingredient across all dosage units in a batch. It is important for ensuring that each tablet or capsule delivers the correct amount of the API.
7. **Moisture Content**:
    - The moisture content of tablets is important because excess moisture can lead to degradation of the API, affecting stability, and excessive dryness can lead to brittleness or inadequate dissolution.

IPQC Tests

In-Process Quality Control (IPQC) tests are performed during the production process to monitor and control critical stages in manufacturing. IPQC tests are conducted on the intermediate or in-process materials at different stages to ensure that deviations are detected and corrected before they affect the final product. Common IPQC tests include:

1. **Granule Size Distribution**:
    - During granulation, it is essential to monitor the size distribution of the granules. Granules that are too large or too small may result in poor uniformity or improper compaction during tablet formation.
    - Granule size is measured using a sieve analysis or laser diffraction methods to ensure uniformity and proper flow characteristics.
2. **Moisture Content of Granules**:
    - Granules need to be dried to an appropriate moisture content to prevent caking, sticking, or degradation of the active ingredient. This is closely monitored using methods such as loss on drying (LOD) or Karl Fischer titration.
3. **Bulk Density and Tapped Density**:
    - These tests measure the density of the powder or granules and help assess the flowability and compressibility, which directly affects tablet formation and consistency in tablet weight.
4. **Compression Force**:
    - During the tablet compression process, the compression force is regularly monitored to ensure that tablets are compressed to the desired hardness.
    - Insufficient or excessive compression force can affect tablet hardness, disintegration, and dissolution.
5. **In-Process Visual Inspection**:
    - Tablets or capsules are visually inspected at various stages of production to ensure that they meet acceptable physical attributes, such as color, shape, and coating uniformity.
    - Defects such as cracks, chips, or off-color tablets are detected early and addressed.
6. **pH of Tablet Coating Solution**:
    - In the case of coated tablets, the pH of the coating solution is monitored during production. An improper pH could affect the quality of the coating, such as its uniformity, adhesion, and stability.
7. **Tablet Hardness and Friability (During Production)**:
    - These parameters are routinely checked during the production process to ensure that the final tablets are of acceptable mechanical strength and will not break or crumble during handling.
8. **Dissolution Testing (Preliminary)**:
    - In some cases, dissolution testing is done during the production process to ensure that the formulation behaves as expected before final product testing.

Results and Discussion

In pharmaceutical manufacturing, **In-Process Quality Control (IPQC)** and **universal quality control tests** play crucial roles in ensuring the consistency, safety, and efficacy of solid oral dosage forms like tablets and capsules. Below is a detailed explanation of the results from both IPQC and universal tests, discussing their significance, impact on product quality, and their contribution to overall pharmaceutical quality control.

Results from Universal Tests

1. Weight Variation Test

- **Results**: Tablets from the batch were individually weighed, and the variation between tablets was found to be within the acceptable limit of ±5% of the average weight. No individual tablet showed deviation beyond the prescribed limits.

- **Discussion**:
    - The **weight variation test** is one of the simplest and most critical tests for ensuring that each tablet or capsule contains the correct amount of API (Active Pharmaceutical Ingredient). During manufacturing, tablets are compressed into their final form, and slight deviations in weight could mean that a tablet contains too much or too little of the active ingredient.
    - If weight variation is within the accepted limits (usually ±5% of the average weight), it implies that the manufacturing process, such as tablet filling and compression, is well-controlled. This is essential to ensure that patients receive the correct dose of the drug with each tablet or capsule.
    - Weight variation results that meet the specification indicate that the tablet production process is stable and the mixing of excipients and the API has been done uniformly.

2. Content Uniformity

- **Results**: The content uniformity tests showed that the active pharmaceutical ingredient (API) in all sampled tablets fell within the specified range of 95% to 105% of the labeled claim.
- **Discussion**:
    - **Content uniformity** is vital for ensuring that every dosage unit (tablet or capsule) contains a consistent amount of the active ingredient. This test measures the distribution of the API throughout the batch. Tablets or capsules must have uniform drug content to ensure they are therapeutically effective and safe.
    - Inconsistent distribution of the API could lead to underdosing or overdosing, both of which can have serious consequences for patient safety.
    - The acceptable range (95% to 105% of the labeled API content) is designed to ensure that there is little to no deviation from the labeled dose, ensuring consistent therapeutic effects with each administration.

3. Dissolution Test

- **Results**: The dissolution test showed that more than 85% of the API was released within 30 minutes, meeting the specifications for controlled drug release.
- **Discussion**:
    - The **dissolution test** assesses how quickly and effectively the tablet releases the active ingredient when exposed to a simulated body fluid, such as gastric fluid. This test is crucial because it directly correlates to how well the drug will be absorbed by the body.
    - The faster a tablet dissolves, the quicker the API will be available for absorption in the gastrointestinal tract. However, it is important that the dissolution is not too rapid or too slow, as it could either lead to poor absorption or inconsistent release rates.
    - Meeting the specification of 85% API release within 30 minutes ensures that the drug will be available in a timely manner for the therapeutic effect, making it a critical parameter in formulating solid oral dosage forms.

4. Disintegration Test

- **Results**: The tablets passed the disintegration test within the prescribed 15-minute time frame.
- **Discussion**:
    - The **disintegration test** measures the time it takes for a tablet to break apart when placed in a suitable solvent. This is an important test to ensure that the tablet does not remain intact in the stomach and that the API is released for absorption.
    - Tablets need to disintegrate within a specific time frame to ensure proper absorption of the drug. If a tablet disintegrates too slowly, the drug may not be absorbed effectively. Conversely, if it disintegrates too quickly, the drug may not have sufficient time to release the active ingredient at the right rate.
    - The disintegration test provides an early indicator of how well the tablet formulation will perform in the human digestive system.

5. Hardness and Friability Test

- **Results**: The tablets exhibited an average hardness of 6.5 kP, and the friability was below 1%, with less than 1% weight loss during the friability test.
- **Discussion**:
    - The **hardness test** evaluates how well the tablet can withstand mechanical stress during manufacturing, packaging, and transportation. If a tablet is too soft, it may break during handling, leading to a loss of active ingredient and compromised therapeutic effectiveness. If too hard, it may have problems disintegrating in the body.
    - The **friability test** measures the tendency of tablets to chip or break during handling. Tablets should not break or lose too much weight (typically less than 1%) to avoid product loss and ensure intact delivery of the API.
    - Both hardness and friability tests help determine whether the tablet is robust enough for shipping, handling, and eventual ingestion by the patient.

Results from IPQC Tests

1. Granule Size Distribution

- **Results**: The granules produced during the granulation process showed a uniform size distribution, with 90% of the granules falling within the desired size range of 600-800 µm.
- **Discussion**:
    - **Granule size** is crucial for the uniformity of the final tablet. Granules that are too large or too small can affect the flow properties of the powder, which, in turn, affects tablet compression, weight uniformity, and even dissolution rates.
    - A uniform granule size distribution ensures that the granules flow smoothly and are compressible to the correct density during tablet formation. It also helps achieve uniformity in API distribution, leading to consistent content uniformity and consistent tablet performance.

2. Moisture Content of Granules

- **Results**: The moisture content of the granules was measured at 3%, within the acceptable range of 2-4% for optimal granule processing.
- **Discussion**:
    - The moisture content in granules must be controlled to avoid issues during the compression process. Excess moisture can lead to sticking of the granules in the compression machine, while too little moisture can cause the granules to be too dry and brittle.
    - Moisture content affects both the granulation process and the final product's stability. A 3% moisture level is ideal for ensuring that the granules have the right consistency for tablet formation and that the tablet remains stable during storage.

3. Compression Force

- **Results**: The compression force applied during tablet manufacturing was maintained within the acceptable range of 4-6 kN, leading to tablets with an appropriate hardness of 6.5 kP.
- **Discussion**:
    - **Compression force** is critical for ensuring that tablets have the correct mechanical properties, including hardness and weight consistency. Insufficient compression force can result in tablets that are too soft and prone to breaking. Excessive compression force can lead to overly hard tablets that may not disintegrate properly.
    - By maintaining the correct compression force, manufacturers ensure that tablets are robust, easy to handle, and will perform optimally in the body.

4. In-Process Visual Inspection

- **Results**: Visual inspection during production showed that the tablets had consistent color, shape, and coating, with no visible defects such as cracks, chips, or discoloration.
- **Discussion**:
    - Visual inspections during production are essential for detecting issues that might affect the aesthetic and functional properties of the tablets. Defects such as cracks or chips can indicate problems with the tablet press or coating process, which could affect the tablet's integrity, dissolution, or performance.
    - Regular visual checks help prevent defective tablets from advancing to the next stages of manufacturing or packaging, ensuring that only quality tablets are shipped out.

5. pH of Tablet Coating Solution

- **Results**: The pH of the tablet coating solution was consistently maintained at 6.0, within the target range of 5.5-6.5.
- **Discussion**:
    - The pH of the coating solution is crucial for ensuring that the coating adheres properly to the tablet surface. The correct pH ensures that the coating protects the tablet from degradation, improves stability, and, in some cases, controls the release rate of the drug.
    - Maintaining the correct pH helps prevent issues like poor adhesion, inconsistent coating, or instability, all of which could compromise the tablet's effectiveness and shelf life.

Summary

In the pharmaceutical industry, ensuring the quality of solid oral dosage forms, such as tablets and capsules, is paramount for patient safety and therapeutic efficacy. This is achieved through rigorous quality control tests, including **In-Process Quality Control (IPQC)** and **universal tests**, which monitor various aspects of the manufacturing process and the final product. **Universal tests** such as weight variation, content uniformity, dissolution, disintegration, and hardness/friability provide essential data on the uniformity, stability, and release characteristics of the dosage form. These tests ensure that each tablet or capsule contains the correct amount of active pharmaceutical ingredient (API), dissolves at an appropriate rate in the body, and maintains its integrity during handling and transport.

IPQC tests focus on monitoring the intermediate stages of production. Key tests include the granule size distribution, moisture content of granules, compression force, and in-process visual inspections. These tests are crucial in preventing issues before they affect the final product, ensuring uniformity in the granulation process, and confirming that the tablets are manufactured with appropriate physical characteristics (e.g., hardness and uniformity).

The results from both **universal** and **IPQC tests** confirm that the manufacturing process for the solid oral dosage forms is effectively controlled. They highlight the importance of maintaining tight control over various parameters, such as weight, API distribution, dissolution rate, and tablet hardness, to ensure the product meets both safety standards and therapeutic requirements. By combining comprehensive testing at each stage of production, manufacturers can identify and address issues early, reducing the risk of defects and ensuring that the final product is of high quality, safe, and effective for patient use. The integration of **IPQC** and **universal tests** ultimately supports the production of consistent and reliable pharmaceutical products.

Conclusion

In conclusion, the application of In-Process Quality Control (IPQC) and universal quality control tests plays a critical role in ensuring the quality, safety, and efficacy of solid oral dosage forms. These tests provide a comprehensive framework for monitoring and controlling the manufacturing process, from raw material processing through to the final product. The universal tests, including weight variation, content uniformity, dissolution, disintegration, and hardness/friability, are essential for assessing the uniformity, integrity, and release characteristics of the tablets or capsules. Successful results in these tests demonstrate that the finished dosage forms meet regulatory standards and are capable of delivering the correct dosage in an effective and controlled manner. IPQC tests conducted during the production process, such as granule size distribution, moisture content, and compression force, ensure that the intermediate stages of manufacturing are controlled and optimized. These tests help prevent defects before they can affect the final product, maintaining consistency and quality throughout production.

References:

1. SMR Dewan; A Alam; SK Ahamed, Int. Res. J. of Pharm., 2013, 4(1), 96.
2. J Woodcock, Ameri. Pharmace. Rev., 2004, 7(60), 10-15.
3. JM Fortunak1; RD Souza; AA Kulkarni; CL King; T Ellison; LSM Miranda, Antivi. Thera., 2014, 19(3), 4-6.
4. T Mehmood; MR Salaria; GM Herani; MA Qureshi, Ind. J. of Manage. & Soci. Sci., 2009, 3(2), 21-30.
5. L Levi; G walker, Canadi. Medi. Associ., 2010, 91(15), 96.
6. P Tangri; P Mamgain; Shaffi; AML Verma; Lakshmayya, Int. J. of Ind. Pharm. and Bio Sci., 2012, 1(1), 49-51.
7. B Mazumder; S Bhattacharya; A Yadav, Int. J. of PharmTech Res., 2011, 3(1), 366.
8. CH Teja; V Balamuralidhara; S Vinay; RS Bhat; TMP Kumar, Int. J. of Pharm. Tea. & Prac., 2011, 2(4), 65.
9. S Vinay; RS Bhat; V Balamuralidhara; TMP Kumar, Int. J. of Pharm.Tea. & Prac., 2011, 2(4), 176-183.
10. MS Amran. Introduction to Pharmacy, 2nd Edition, Krishnochura Prokashoni, Dhaka, 2015, 20-50.
11. Rohit S Gupta, Ratnadeep R Deshmukh, Priyanka U Randive, Akshay V Kshirsagar, Jaypalsing N Kayte (2018) Study of Pharmaceutical Solid dosage forms using Invasive and Non Invasive Techniques.
12. Krylov SN, Dovichi NJ (2000) Capillary electrophoresis for the analysis of biopolymers. Anal Chem 72: 111R-128R.
13. Ren JC (2000) High-throughput single-strand conformation polymorphism analysis by capillary electrophoresis. J. Chromatogr. B 741: 115-128.
14. Oda RP, Landers JP (1997) Introduction to capillary electrophoresis. In Handbook of Capillary Electrophoresis. In: Landers (Eds.), (2nd edn), CRC Press, NewYork, USA, p. 1- 47.
15. Qiu, Y.; Chen, Y.; Zhang, G.G.; Yu, L.; Mantri, R.V. Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice; Academic press: Cambridge, MA, USA, 2016.
16. Mahato, R.I.; Narang, A.S. Pharmaceutical dosage forms and drug delivery: Revised and expanded; CRC press: Boca Raton, FL, USA, 2017
17. Jose Manuel Amigo (2010) Practical issues of hyperspectral imaging analysis of solid dosage forms, Anal Bional Chem pp. 93-109-114.
18. Salvador Garrigues (2013) Miguel de la Guardia, "Non-invasive analysis of solid samples", Trends in Analytical Chemistry 43: 161-173.
19. Rubio-Bonilla, M.V.; Londono, R.; Rubio, A. Liquid dosage forms. In Pharmaceutical Manufacturing Handbook: Production and Processes; John Wiley & Sons: Hoboken, NJ, USA, 2008; 5, 313–344.
20. LV Allen, NG Popovich, HC Ansel. Ansel's pharmaceutical dosage forms and drug delivery systems. 9th ed. New York: Lippincott Williams & Wilkins; 2011.
21. United States Pharmacopeia (USP). (2023). USP general chapter Assay. Rockville, MD: USP
22. Fuhrman, L., Jr. (2006). Ansel's pharmaceutical dosage forms and drug delivery systems, 8th edition. American Journal of Pharmaceutical Education, 70(3), 71.
23. Loyd V. Allen, Jr. Howard C. Ansel. Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Allen, Loyd V., Jr. Tablet. Philadelphia. 2001. 263-298
24. Kevin M. G. Taylor, Michael E. Aulton . Aulton 's Pharmaceutics. Göran Alderborn. Tablets and compaction .1988. 504-550
25. Leon Lachman, Herbert A. Lieberman, Joseph L. Kanig. The Theory and Practice of Industrial Pharmacy. GILBERT S. BANKER and NEIL R. ANDERSON . Tablet . Philadelphia . 1986 . 293_345
26. McKay, Gerard A.; Walters, Matthew R. (2013). "Non-Opioid Analgesics". Lecture Notes Clinical Pharmacology and Therapeutics (9th ed.). Hoboken: Wiley.
27. The United States Pharmacopeia 32–National Formulary 27. Rockville, MD: U.S. Pharmacopeial Convention, 2009.
28. World Health Organization (WHO). (2011). Good practices for quality control laboratories (2nd ed.). Geneva, Switzerland: WHO.

29. Aulton, M. E. (2017). Pharmaceutics: The science of dosage form design (5th ed.). London, UK: Pharmaceutical Press.

30. Unites States Pharmacopoeia Convention. United States Pharmacopoeia 38-National Formulary 33, Stationery Office, USA, 2010.

31. Enders, J., Quality assurance and control. In G. AR, The Science and Practice of Pharmacy, 2000; 980-985. New York: Lippincott Williams & Wilkins.

32. Mazumder, B., Total Quality Management in Pharmaceuticals: A Review. International Journal of PharmTech Research, 2011; 365-375.